Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents

Alberto Auricchio; Kathryn C. Behling; Albert M. Maguire; Erin E. O'Connor; Jean Bennett; James M. Wilson; Michael J. Tolentino

doi:10.1006/mthe.2002.0702

Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents

Alberto Auricchio, Kathryn C. Behling, Albert M. Maguire, Erin E. O'Connor, Jean Bennett, James M. Wilson, Michael J. Tolentino

Research output: Contribution to journal › Article › peer-review

145 Scopus citations

Abstract

Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes of severe visual loss in the developed world. Gene transfer to the eye using adeno-associated viral (AAV) vectors is a promising new treatment for inherited and acquired ocular diseases. We used an AAV vector with rapid onset and high levels of gene expression in the retina to deliver three anti-angiogenic factors (pigment epithelium-derived factor, tissue inhibitor of metalloproteinase-3, and endostatin) to the eyes of mice in a mouse model of retinopathy of prematurity. All three vectors inhibited ischemia-induced neovascularization.

Original language	English (US)
Pages (from-to)	490-494
Number of pages	5
Journal	Molecular Therapy
Volume	6
Issue number	4
DOIs	https://doi.org/10.1006/mthe.2002.0702
State	Published - Oct 1 2002
Externally published	Yes

All Science Journal Classification (ASJC) codes

Molecular Medicine
Molecular Biology
Genetics
Pharmacology
Drug Discovery

Access to Document

10.1006/mthe.2002.0702

Cite this

@article{95104d3599804cc78717c547a5152830,

title = "Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents",

abstract = "Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes of severe visual loss in the developed world. Gene transfer to the eye using adeno-associated viral (AAV) vectors is a promising new treatment for inherited and acquired ocular diseases. We used an AAV vector with rapid onset and high levels of gene expression in the retina to deliver three anti-angiogenic factors (pigment epithelium-derived factor, tissue inhibitor of metalloproteinase-3, and endostatin) to the eyes of mice in a mouse model of retinopathy of prematurity. All three vectors inhibited ischemia-induced neovascularization.",

author = "Alberto Auricchio and Behling, {Kathryn C.} and Maguire, {Albert M.} and O'Connor, {Erin E.} and Jean Bennett and Wilson, {James M.} and Tolentino, {Michael J.}",

note = "Funding Information: This work was funded by the Juvenile Diabetes Foundation International (M.J.T., J.B., and J.M.W.), NEI KO8 EY 13410-01, the RPB Career Development award, the International Retinal Research Foundation (M.J.T.), NIH (RO1-EY10820, RO1-EY12156, T32-EY-07035, P30 DK47757-09), Foundation Fighting Blindness, Research to Prevent Blindness, the LIFE Foundation and the Steinbach Foundation (J.B. and K.C.B.), and GlaxoSmithKline (J.M.W.). J.M.W. holds equity in Targeted Genetics. Help from the Cell Morphology Core of the Institute for Human Gene Therapy is acknowledged.",

year = "2002",

month = oct,

day = "1",

doi = "10.1006/mthe.2002.0702",

language = "English (US)",

volume = "6",

pages = "490--494",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents

AU - Auricchio, Alberto

AU - Behling, Kathryn C.

AU - Maguire, Albert M.

AU - O'Connor, Erin E.

AU - Bennett, Jean

AU - Wilson, James M.

AU - Tolentino, Michael J.

N1 - Funding Information: This work was funded by the Juvenile Diabetes Foundation International (M.J.T., J.B., and J.M.W.), NEI KO8 EY 13410-01, the RPB Career Development award, the International Retinal Research Foundation (M.J.T.), NIH (RO1-EY10820, RO1-EY12156, T32-EY-07035, P30 DK47757-09), Foundation Fighting Blindness, Research to Prevent Blindness, the LIFE Foundation and the Steinbach Foundation (J.B. and K.C.B.), and GlaxoSmithKline (J.M.W.). J.M.W. holds equity in Targeted Genetics. Help from the Cell Morphology Core of the Institute for Human Gene Therapy is acknowledged.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes of severe visual loss in the developed world. Gene transfer to the eye using adeno-associated viral (AAV) vectors is a promising new treatment for inherited and acquired ocular diseases. We used an AAV vector with rapid onset and high levels of gene expression in the retina to deliver three anti-angiogenic factors (pigment epithelium-derived factor, tissue inhibitor of metalloproteinase-3, and endostatin) to the eyes of mice in a mouse model of retinopathy of prematurity. All three vectors inhibited ischemia-induced neovascularization.

AB - Neovascularization characterizes diabetic retinopathy and choroidal neovascularization associated with age-related macular degeneration, the most common causes of severe visual loss in the developed world. Gene transfer to the eye using adeno-associated viral (AAV) vectors is a promising new treatment for inherited and acquired ocular diseases. We used an AAV vector with rapid onset and high levels of gene expression in the retina to deliver three anti-angiogenic factors (pigment epithelium-derived factor, tissue inhibitor of metalloproteinase-3, and endostatin) to the eyes of mice in a mouse model of retinopathy of prematurity. All three vectors inhibited ischemia-induced neovascularization.

UR - http://www.scopus.com/inward/record.url?scp=0036798747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036798747&partnerID=8YFLogxK

U2 - 10.1006/mthe.2002.0702

DO - 10.1006/mthe.2002.0702

M3 - Article

C2 - 12377190

AN - SCOPUS:0036798747

SN - 1525-0016

VL - 6

SP - 490

EP - 494

JO - Molecular Therapy

JF - Molecular Therapy

IS - 4

ER -

Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this